Synagis Morning Symposium

Click below to register for the
2023 Pediatric Academic Societies Meeting
Respiratory Syncytial Virus in certain high-risk
preterm and medically fragile infants
Multi-disciplinary panel discussion – Ancillary event

Saturday, April 29 | 7 am ET
Marriott Marquis, Washington, DC 20001 | 901 Massachusetts Ave NW

*Registration required to participate

I will be joining virtually

I will be joining in person at the Marriott

For additional information email: SYNAGIS_Marketing_US@sobi.com

INDICATION
SYNAGIS, 50 mg and 100 mg for injection, is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients:

with a history of premature birth (≤35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season
with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season
with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season

LIMITATIONS OF USE
The safety and efficacy of SYNAGIS have not been established for treatment of RSV disease.
CONTRAINDICATIONS
Previous significant hypersensitivity reaction to SYNAGIS.

IMPORTANT SAFETY INFORMATION
Hypersensitivity Reactions: Anaphylaxis and anaphylactic shock (including fatal cases) and other severe acute hypersensitivity reactions have been reported. Permanently discontinue SYNAGIS and administer appropriate medication if such reactions occur.
Coagulation Disorders: SYNAGIS should be given with caution to children with thrombocytopenia or any coagulation disorder.
RSV Diagnostic Test Interference: Palivizumab may interfere with immunological-based RSV diagnostic tests, such as some antigen detection-based assays.
Serious Adverse Reactions: The most common serious adverse reactions occurring with SYNAGIS are anaphylaxis and other acute hypersensitivity reactions.
Most Common Adverse Reactions: The most common adverse reactions are fever and rash.
Postmarketing Experience: Severe thrombocytopenia and injection site reactions have been identified during post approval use of SYNAGIS. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
These are not all the possible risks associated with SYNAGIS.
Please click here for full Prescribing Information for SYNAGIS, including Patient Information.
To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or the FDA at 1-800-FDA-1088